

****New release March 2009****

DiseaseINFOPACK: pre-pandemic vaccines (CAT: VADIP010)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	Comprehensive review/analysis of pre-pandemic planning, H5N1 vaccines and early priming
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Pandemic influenza, H5N1</i>
Product (if applicable)	:	CAT No: VADIP010, published March 2009

Background

Experts commonly believe that the next influenza pandemic is imminent. They are particularly concerned about the current avian influenza strain H5N1 (and subclades) which has spread rapidly in bird populations in SE Asia. H5N1 has caused high mortality in poultry and occasionally infects humans in close contact with around 60% of cases (408) so far being fatal¹. As of December 3rd 2008, 67 cumulative countries have experienced H5N1 avian influenza in animals which is an alarming increase on the 11 countries counted in 2004². As of February 27th confirmed H5N1 Avian influenza deaths in humans have reached 256, again a significant increase upon 2004. A simultaneous infection of a human influenza virus and H5N1 could cause genetic reassortment forming a new virus that can be spread more rapidly between humans initiating a pandemic. To date H5N1 has not been reported in the Western Hemisphere.

Many governments around the world have drawn up detailed plans specifying how they would deal with an influenza pandemic once its emergence was detected. A large focus is placed on ensuring mechanisms can ensure the swift and efficient production of pandemic specific influenza vaccines using both egg-based and cell-based systems. Other government measures have included the stockpiling of H5N1 pre-pandemic vaccines with the assumption that vaccine could provide cross-protective priming immunity to the eventual pandemic strain. For example, The US government (HHS) has procured 12.2 million treatment courses

¹ World Health Organization (WHO). Website. Available at:

http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_02_27/en/index.html. Accessed: March 2009.

² Pandemic Planning Update VI. A report from Secretary Michael O. Leavitt. US Department of Health and Human Services, January 8, 2009. Accessed: March 2009.

of H5N1 vaccine mainly allocated to support clinical trials and protect “front-line” healthcare workers, first responders and other critical tier 1 workers²

This expert report provides a comprehensive up-to-date review of the current status of pandemic preparedness and planning with regarding the overarching World Health Organisation (WHO) objectives/strategies and key features of major Western countries pandemic preparedness plans. A particular emphasis is placed on the role of pre-pandemic vaccines, pandemic specific vaccines relative to other pandemic countermeasures. The report captures the viewpoints of 5 recognised global opinion leaders and discusses current arguments for and against “early” pre-pandemic priming and potential impacts on seasonal influenza vaccination.

PRODUCT CONTENTS:

Published March 2009 (CAT No: VADIP010)

- Foreword
- Contents
- Experts interviewed as part of this research
- Executive summary
- Pandemic preparedness: Role of WHO
- Expert viewpoints: pandemic preparedness
- WHO Strategic action plan
- WHO: Six stages of pandemic alert
- Stages of pandemic alerts: revisions for 2008
- US HHS stockpile goals for pandemic preparedness
- Expert viewpoints: US preparedness
- US HHS funding for influenza pandemic preparedness 2004-2008
- US pandemic vaccine(s): review of objectives
- Pre-pandemic vaccine: implementation (US)
- US HHS awards for cell-based influenza vaccines
- US pandemic vaccine(s): points to note
- US HHS planning: Congressional Budget Office (CBO) review
- US framework for targetting pandemic specific vaccine
- US estimated number in vaccine target groups
- US estimated numbers in vaccine tiers
- Expert viewpoints: subcategorizing the population
- Sub prioritization of tier 1
- Possible phasing of pandemic vaccines
- Expert viewpoints: release of stockpile (US) and general
- Canada: pandemic specific vaccine objectives
- Canada: framework for targetting pandemic specific vaccine
- Canada: factors influencing subgroup prioritization
- Canada: pre-pandemic vaccine status
- Expert viewpoints: UK preparedness
- UK: framework for targetting pandemic specific vaccine
- UK: anticipated demand of pandemic specific vaccine
- UK: implementation of pandemic specific vaccination
- UK: pre-pandemic vaccination

Expert Viewpoints: UK pandemic preparedness
France: summary of pandemic vaccine planning
Spain: summary of pandemic vaccine planning
Italy: summary of pandemic vaccine planning
Australia and pandemic plan: phases of health response
Australia: summary of pandemic vaccine planning
Japan: summary of pandemic vaccine planning
Pre-pandemic vaccine stockpiling: country summary
Advance supply commitments: country summary
Expert Viewpoints: comments on advanced supply agreements
“Early” pre-pandemic priming: drivers and resisters
Expert Viewpoints: “early” priming strategy
Expert Viewpoints: combining H5 with seasonal vaccine
“Early” pre-pandemic priming – possible rollout strategy
Pandemic vaccine: impacts on seasonal market
Pre-Pandemic planning: brief comments on the business sector
Pre-Pandemic planning: brief comments on a consumer model
Appendix I – US HHS: summary of planning actions to date
Appendix I – Bibliography
Appendix II – About VacZine Analytics
Disclaimer

PAGES: ~70 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

PROJECT METHODOLOGY:

VacZine Analytics has conducted a comprehensive secondary research to review all available information regarding pre-pandemic and pandemic specific vaccines in major EU/Canada and US markets. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

Published research from **VacZine Analytics** has also been utilised.

****NOTE**** 5 International global opinion leaders/experts in pandemic influenza were interviewed as part of this research. Their contribution is anonymous.

BIBLIOGRAPHY:

1. WHO activities in avian influenza and pandemic influenza preparedness. Jan-Dec 2006. Available at: http://www.who.int/csr/disease/avian_influenza/WHO_CDS_EPR_GIP_2006_6.pdf Accessed January 2009
2. Revision of the Pandemic Influenza Preparedness Guidance – An Update on the Drafting Process. July 2008. Available at: http://www.who.int/csr/disease/influenza/PPWGupdate_WHOWebVersion.pdf. Accessed March 2009
3. Influenza Pandemic. HHS Needs to Continue Its Actions and Finalize Guidance for Pharmaceutical Interventions. United States Government Accountability Office (GAO). September 2008.
4. Congressional budget office (CBO) of the United States. September 2008. US Policy Regarding Pandemic Influenza Vaccines. Available at: <http://www.cbo.gov/ftpdocs/95xx/doc9573/09-15-PandemicFlu.pdf> Accessed February 2009
5. Levitt MO. US Department of Health and Human Services (HHS). Pandemic Planning Update VI. January 8, 2009. Available at: <http://www.pandemicflu.gov/plan/pdf/panflureport6.pdf>. Accessed January 2009.
6. Guidance on allocating and targetting pandemic influenza vaccine. US Department of Health and Human Services. Available at: <http://www.pandemicflu.gov/vaccine/allocationguidance.pdf>. Accessed March 2009
7. Public Health Agency of Canada. Preparing for the Pandemic Vaccine Response, September 2008. Annex D. Available at: http://www.phac-aspc.gc.ca/cpip-pclcpi/pdf-e/annex_d-eng.pdf. Accessed March 2009

8. UK Department of Health. Pandemic influenza : guidance for primary care trusts and primary care professionals on the provision of Healthcare in the Community Setting in England. Available at:
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_080757. Accessed March 2009
9. UK Health Protection Agency (HPA) Pandemic influenza Contingency Plan. Available at:
http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947380783 Accessed March 2009
10. French Pandemic Preparedness Plan. General Secretariat of National Defense. Available at:
http://www.grippeaviaire.gouv.fr/IMG/pdf/Plan_version_anglaise.pdf. Accessed March 2009
11. National Influenza Preparedness and Response Plan. Available at:
<http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/docs/PlanGripeIngles.pdf>. Accessed March 2009
12. Italian Ministry of Health. Available at:
http://www.eiss.org/documents/Italian_Plan_For_Preparedness_And_Response_To_An_Influenza_Pandemic_-_English_version.pdf Accessed March 2009
13. Australian Health Management Plan for Pandemic Influenza (AHMPPI). Available at:
[http://www.flupandemic.gov.au/internet/panflu/publishing.nsf/Content/8435EDE93CB6FCB8CA2573D700128ACA\\$File/Pandemic%20FINAL%20webready.pdf](http://www.flupandemic.gov.au/internet/panflu/publishing.nsf/Content/8435EDE93CB6FCB8CA2573D700128ACA$File/Pandemic%20FINAL%20webready.pdf). Accessed March 2009
14. Western Australian Government. Human Influenza Pandemic Plan. November 2008. Available at:
<http://www.ossec.dpc.wa.gov.au/documents/planHumanInfluenzaPandemicWAGov.pdf>. Accessed March 2009
15. Japan Vaccination Guideline for Pandemic Influenza. March 26th 2007. Available at:
<http://www.mhlw.go.jp/bunya/kenkou/kekaku-kansenshou04/pdf/09-e09.pdf> . Accessed March 2009
16. H5N1 Pre-pandemic Vaccine Plans in Japan. Recombinomics Press Release. Available at:
http://www.recombinomics.com/News/04180803/H5N1_Pre_Pandemic_Japan.html. Accessed March 2009.

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o **USD \$6995.00/ GBP £4695.00 (Region license)***

*A region is North America, Europe or ROW

For orders in the UK, VAT at 15% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009



VacZine Analytics[®]
Bringing life to vaccine strategy...

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

